Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.
about
The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical toolsAntibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties.B-cell epitopes in the immunodominant p34 antigen of mycobacterium avium ssp. paratuberculosis recognized by antibodies from infected cattle.Passive administration of monoclonal antibodies to anthrolysin O prolong survival in mice lethally infected with Bacillus anthracisPeptide mimic of phosphorylcholine, a dominant epitope found on Streptococcus pneumoniaeCharacterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Role of the Apt1 protein in polysaccharide secretion by Cryptococcus neoformans.Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleBivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infectionThe different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.Antibody interactions with the capsule of Cryptococcus neoformansImmunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigenPhenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous systemFungal vaccines and immunotherapeutics.Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.Effect of human immunodeficiency virus infection on plasma bactericidal activity against Salmonella enterica serovar Typhimurium.Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodiesCryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct.Host defence to pulmonary mycosisHuman immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding.Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannanCombinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformansThe capsule of the fungal pathogen Cryptococcus neoformans.Catch me if you can: phagocytosis and killing avoidance by Cryptococcus neoformans.The protective role of immunoglobulins in fungal infections and inflammation.Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis.An opsonizing monoclonal antibody that recognizes a noncapsular epitope expressed on Cryptococcus neoformans.Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure.Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter.Monoclonal antibody 13F1 produces annular immunofluorescence patterns on Cryptococcus neoformans serotype AD isolates
P2860
Q28087622-5792563D-CCCD-4368-B37B-F8811E414159Q30530667-CA7F7244-3ABB-4A13-A936-98A2740126DFQ31027682-31A3138E-290A-4D39-8DB3-4EFBB09A3DD1Q33371386-9B770D63-B98B-474F-AB6A-3348EE58A751Q33592253-99F057FD-EFFC-4949-8807-7DD8A4552556Q33693515-2778DD0A-141E-40B1-9323-CA978C14F7C5Q33743568-3FC51599-F5F6-4CE7-AB2B-8E188B834DFFQ33752366-9DF6E8C2-7387-48DB-8DDE-5FBD257BEE63Q33752377-E8C81A7C-6EFA-4E49-A3C0-E0F72A7F363BQ33755308-86E7D653-D00B-49D0-9276-E24146A37A5FQ33766953-90B448CA-257E-43B8-AE59-2BD10B86495CQ33991158-656DF297-6C43-4B75-9902-77CC85D9CEF7Q34001243-E7AC0639-D10A-4653-B5FF-1B7702A2C315Q34004832-34579B65-F803-46EE-BE9C-33D0917FE58EQ34121516-65828237-E907-44FE-84E5-37533E7197DAQ34146715-5FA291BE-DF1E-4FF5-9EB3-F3D76004F499Q34334384-14908972-2CB6-47E2-A3D6-EA30B7EEECE5Q34400249-EA306C91-6D71-4D24-87E3-29835CABCBAFQ34594241-18B84C5F-F0BE-4450-8C89-79C3B7A6256EQ34701418-A39FCEC8-6E7C-472D-B76B-D33A7C9A2794Q34757345-6D606AED-E850-4F3F-8FF5-7E0874C22637Q34961105-C973E699-7B03-493F-AF9E-1169DDB9BB37Q35649657-F06257D0-1923-4C23-9234-143E542CE253Q35689463-D7C3D0C2-2199-4C7A-98D5-01636B241F0CQ35913526-F7715A2B-C946-4338-AE38-CC862CE9BA19Q36228216-F477DCA5-3249-4777-B0AA-5530175BE45BQ36350251-F7CE0A3F-94AF-4BE3-9927-46932DB653F5Q36446429-AC1C314E-C4C4-4D8C-8A6F-9DDDF90A6486Q36844895-604A0994-296B-4297-8281-4552C7E24A4CQ36911369-037EF3DC-04FC-4927-90FA-E13451DA087FQ37033075-E4F7F8B6-E325-43F5-910F-720830F1B180Q37337879-7C17BA2C-CD80-4ECD-9B75-1FC59ECF2E8FQ37949657-E0893ABC-E40E-46CC-B64B-709EDE2F3F14Q38268922-3FCD5D7E-C342-4163-BC22-4D8B8735EEF9Q39468908-6E3A3AE2-562D-4D52-AD83-EC3B87DAFFE9Q39512151-F068A195-3ED6-4EE6-8A03-E88908A3E501Q39512897-F4C795D1-017B-407B-85DF-7789C1FA5E76Q39520077-9C2AA694-DCB2-4E63-B6D9-F534B1343BE8Q39693119-89FCC48D-8DA3-45DC-8D5C-E02586E747BBQ42725627-949D5827-5F45-4D76-B778-34ECBFCC0193
P2860
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Epitope location in the Crypto ...... erminant of antibody efficacy.
@ast
Epitope location in the Crypto ...... erminant of antibody efficacy.
@en
type
label
Epitope location in the Crypto ...... erminant of antibody efficacy.
@ast
Epitope location in the Crypto ...... erminant of antibody efficacy.
@en
prefLabel
Epitope location in the Crypto ...... erminant of antibody efficacy.
@ast
Epitope location in the Crypto ...... erminant of antibody efficacy.
@en
P2093
P2860
P356
P1476
Epitope location in the Crypto ...... erminant of antibody efficacy.
@en
P2093
A Casadevall
G Nussbaum
M D Scharff
P2860
P304
P356
10.1084/JEM.185.4.685
P407
P577
1997-02-01T00:00:00Z